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Introduction
Distal renal tubular acidosis (dRTA) is a defect in
urinary acidification characterized by an inability
to acidify the urine to (conventionally) pH <5.5, even
in the presence of systemic acidaemia; it is often
associated with nephrocalcinosis, recurrent renal
calculi and reduced bone mineral density. The under-
lying causes of this syndrome are several: it may be
inherited or secondary to other conditions, such as
autoimmune disease (notably Sjo¨gren’s syndrome),
drug therapy or nephrocalcinosis itself [1].
Inherited dRTA can be recessive or autosomal
dominant: the autosomal dominant form is invariably
(and the recessive form occasionally) associated with
mutations in the gene SLC4A1, which encodes for
the membrane protein Anion Exchanger 1 (AE1). This
transport protein in the kidney is expressed on the
basolateral membrane of a-intercalated cells, where it
plays a key role in linking apical Hþ-ATPase-mediated
proton secretion to basolateral bicarbonate efflux;
ultimately controlling net urinary acidification and
systemic acid–base balance. AE1 is highly expressed in
erythrocytes and the kidney, and different mutations
in this protein may cause red-cell defects (spherocytosis
or Southeast Asian ovalocytosis) or dRTA. A number
of dRTA-causing mutations of SLC4A1 have now
been described and characterized in several in vitro cell
systems [2].
When dRTA-causing AE1 mutants are expressed
in the non-polarized oocyte, they retain significant
anion transport activity [2,3], in contrast to the poorly
or non-functioning AE1 mutants associated with
red-cell disorders. This finding led to the hypothesis
that these mutations may cause a membrane traffick-
ing, rather than a functional, defect in the AE1 protein.
Recent in vitro studies seem to support this view, since
various dRTA-associated AE1 mutants expressed in
polarized renal epithelial cells in culture are either
retained in the cytosol or mistargeted to the apical
membrane [4–6]. However, little work has been
possible on native human renal tissue, as only damaged
kidney material from surgery or at post-mortem has
been available, and a renal biopsy is not usually
justified in the diagnosis or management of dRTA [7].
We have obtained tissue from a patient with a
unique SLC4A1 mutation, S613F [3] and tissue from
another patient with autoimmune dRTA, probably as
part of Sjo¨gren’s syndrome. In this report, we describe
the clinical features of each patient and the immuno-
histochemical findings with antibodies directed
against the AE1 protein or the vacuolar Hþ-ATPase
(vHþ-ATPase) proton pump.
Cases
Case 1, primary dRTA (S613F AE1 mutation)
A 70-year-old male patient underwent a native renal
biopsy in February 2003. He had been referred
aged 44 years with a 16-year history of recurrent
nephrolithiasis. A plain abdominal X-ray at that time
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showed modest nephrocalcinosis and he was noted to
have a plasma bicarbonate concentration in the low-
normal range (21mmol/l). He had no proteinuria
and his plasma creatinine concentration was 90 mmol/l.
Distal RTA was suspected and he underwent a formal
urinary acidification test: the standard short (8 h)
oral ammonium chloride test, which was positive,
confirming the diagnosis of type 1 dRTA.
Genetic screening as part of our earlier study of
familial autosomal dominant dRTA showed that the
patient and an affected daughter were heterozygous for
a Ser to Phe substitution mutation at position 613
(S613F) in the SLC4A1 gene encoding the anion
exchanger AE1 [3]. His plasma creatinine concentration
was 100mmol/l in 1985 and deteriorated slowly to
139mmol/l in 1995, when a 51Cr-EDTA estimate of his
glomerular filtration rate (GFR) was 46ml/min/1.73m2.
In 1991, he had been noted to have a faint IgG lambda
paraprotein M band on protein electrophoresis, though
too faint to quantify and not associated with any
immune paresis or Bence–Jones proteinuria. He devel-
oped trace to 1þ dipstick proteinuria in 1997 (quantified
at 0.23 g/l in a 24-h sample in 1999), which remained
stable on dipstick testing thereafter. By 2002 his GFR
had fallen to 32ml/min/1.73m2, and together with his
persistent and unexplained slight proteinuria in the
context of a monoclonal gammopathy, it was decided
that he should undergo an elective renal biopsy, to
which he agreed. This was performed and two samples
were obtained.
Case 2, autoimmune dRTA
A 42-year-old female presented with severe
hypokalaemia (1.3mmol/l), proximal muscle weakness,
low-plasma bicarbonate concentration (18mmol/l),
and a spot urine pH of 7.3. Her plasma creatinine
concentration was 57 mmol/l; urea, calcium, phosphate
and magnesium levels were all normal. She was found
to be ANA, anti-Ro/SSA and anti-La/SSB positive
and antiphospholipid antibody positive. She gave
a history of a sicca syndrome with dry mouth and
gritty eyes for some months. Thus, the clinical features
were of hypokalemic dRTA due to autoimmune
disease, probably Sjo¨gren’s syndrome. Repeat of her
autoimmune screen showed her to be ANA positive,
ENA (SSA and SSB) positive, and to have a raised
polyclonal IgG level (22.3 g/l) and borderline low C3
level; there was mild nephrocalcinosis on a plain
abdominal X-ray. However, because of some protein-
uria (<0.5 g/24 h) and a concern that she may have
SLE with antiphospholipid syndrome, a renal biopsy
was performed.
Methods
Sections (2 mm) were cut from archived wax-embedded
human kidney tissue using a microtome, placed on negatively
charged coated slides (X-tra MicroslidesTM, Surgipath, US)
and dried overnight at 378C. (Control tissue was obtained
from an unsuitable donor transplant kidney.) The sections
were subsequently de-waxed with histoclear (National
Diagnostics, Hessle, UK) and rehydrated in decreasing
concentrations of ethanol. Slides were heated in 10mM
citrate buffer in a microwave oven for 10min and allowed
to cool for 1 h, then washed 3 times for 5min with excess
phosphate buffered saline.
Non-specific binding was blocked by incubation with
10% normal horse serum (NHS) (Invitrogen Ltd, Renfrew,
UK) for 30min. Subsequently, the sections were incubated
overnight at room temperature with the primary anti-
bodies diluted in 10% NHS. The primary antibodies used
were monoclonal: Bric 155 against the AE1 C-terminus, Bric
170 against the AE1 N-terminus [8] and E11 against the
E subunit of the vHþ-ATPase (a gift from S. Gluck, UCSF,
USA). Rabbit anti-aquaporin 2 (a gift from D. Marples,
University of Leeds, UK) in a dilution of 1/1000 was used
to positively identify collecting duct principal cells [9].
The following day slides were washed 3 times for 5min,
then incubated for 1 h with secondary antibodies [fluorescein
isothiocyanate (FITC)-coupled anti-mouse IgG (green
colour) (Jackson Immunoresearch, Luton, UK)] and Cy3
labelled anti-rabbit IgG (Abcam, Cambridge, UK) to detect
bound primary antibodies. The specificity of all primary
antibodies has been demonstrated previously [8–10]. There
was no specific staining when the primary antibodies
were omitted. Slides were washed, mounted in Citifluor
(Citifluor Ltd, London, UK) and examined using a Zeiss
Axioplan immunofluorescence microscope and photographs
were taken with a Leica DC200 digital camera (Zeiss,
Go¨ttingen, Germany).
Results
Light microscopy
Case 1. Sections showed renal cortex with 10 glomer-
uli in total, all of which appeared normal. There was
some mild tubular atrophy with a patchy lymphocytic
infiltrate. Scattered foci of calcification were seen.
No significant immuno-deposition was detected.
Case 2. Eight glomeruli were seen: one was sclerosed,
but the others were normal. The tubules looked
normal, but there was a patchy increase in interstitial
fibrosis. There was no significant immuno-deposition
and no features of SLE.
Immunohistochemistry
Control tissue. In control tissue all antibodies directed
against AE1 demonstrated basolateral staining of cells
in the connecting tubule (CNT), cortical (CCD) and
medullary collecting duct. These cells were negative for
the principal cell specific marker aquaporin 2 (AQP2)
and were therefore identified as intercalated cells
(arrows in Figure 1A and B). Notably, the AE1
antibodies also stained red blood cells present in the
tissue (in peritubular capillaries). The distribution
of the vHþ-ATPase along the collecting system
was examined using an antibody (E11) against the
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31 kDa E subunit. Staining was predominantly apical
and sub-apical in most intercalated cells in the CNT
and CCD, and in all intercalated cells along the
OMCD and IMCD (Figure 2A and B). Thus, in
control tissue the majority of intercalated cells showed
positive immunostaining for basolateral AE1 and
apical and sub-apical vHþ-ATPase.
Case 1. Renal tissue from the patient with the S613F
mutation (Figure 1C and D) showed an overall
decrease in the intensity of AE1 immunoreactivity
(compared with control) and marked cytoplasmic
staining (arrows Figure 1C), but no clear basolateral
localization. AE1 staining of red blood cells was also
seen (white arrows Figure 1D). The S613F mutant
tissue showed decreased staining and apparent cyto-
solic localization of vHþ-ATPase in type a-intercalated
cells (identified as being negative for AQP2 staining),
which appeared to be smaller in size and fewer in
number when compared with control tissue (Figure 2D
and E). Shayakul et al. [7] also described reduced
expression of vHþ-ATPase in a-intercalated cells that
were fewer in number.
Case 2. The renal tissue from the patient with
probable Sjo¨gren’s syndrome showed complete
absence of immunoreactivity for AE1 in intercalated
cells (Figure 1E and F), whereas red cells in the tissue
sections showed strong immunoreactivity (Figure 1E).
The vHþ-ATPase staining of intercalated cells in
Fig. 1. In all photomicrographs AQP2 immunostaining (red) identifies principal cells of the collecting duct. All scale bars are 50 mm.
(A) Control human kidney showing Bric 155 antibody immunostaining basolateral kAE1 in the cortical collecting duct. (B) Control human
kidney showing Bric 170 antibody immunostaining basolateral kAE1 in the connecting segment. (C) S613F mutation patient Bric 155
antibody showing kAE1 either cytoplasmic (blue and white arrows) or absent (yellow arrow) in cortical collecting duct. (D) S613F mutation
patient Bric 170 antibody showing cytoplasmic kAE1 (blue arrow) and also strong AE1 expression in coincident erythrocytes (white arrows)
in cortical collecting duct. (E) Sjo¨gren’s patient Bric 155 antibody shows no kAE1 expression in a-intercalated cells. Again, bright
imunofluorescence demonstrates normal AE1 expression on coincident erythrocytes. (F) Sjo¨gren’s patient Bric 170 antibody shows no kAE1
expression in a-intercalated cells.
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the CCD was also negative, demonstrating loss
of immunoreactivity for both kAE1 and vHþ-ATPase
(Figure 2E), consistent with previous findings in
renal tissue from patients with Sjo¨gren’s syndrome
[7,11–13].
Discussion
The most commonly reported dRTA-causing AE1
mutations in Caucasians produce a substitution
of arginine at residue 589 (R589H, R589S and
R589C). The other reported dominant forms are
S613F, A858D, G609D and two truncations at the
C-terminus, R901X (Band 3 Walton) and a 23 amino-
acid deletion [1]. These mutations have substantial
transport activity when expressed in Xenopus Laevis
oocytes [2]. They are expressed normally in the red
cell membrane, in part because of the presence of
glycophorin A, which can also increase their surface
expression in oocytes [3]. These findings suggested
that the kAE1 mutations do not cause a reduction
of transport capacity, raising the possibility that
the mutant protein is either mistargeted to the apical
membrane, or retained in the cell, which is consistent
with the results of in vitro expression studies in
various cell models (Madin–Darby Canine Kidney
cells and Human Embryonic Kidney-293 cells); more-
over, coexpression of autosomal dominant dRTA
mutants and wildtype (wt) kAE1 show retention of
wt kAE1 in the cytoplasm, probably by hetero-
oligomer formation and thus a dominant-negative
effect [4,6].
Fig. 2. In Figures 2B, C and E, red immunostaining with anti-AQP2 identifies principal cells in the collecting ducts. Scale bars are 50 mm.
(A) Control human kidney showing apical immunostaining of vHþ-ATPase in a-intercalated cells in the cortical collecting duct. (B) Control
human kidney showing apical immunostaining of vHþ-ATPase in a-intercalated cells in the cortical collecting duct. (C) S613F mutation
patient vHþ-ATPase expression is cytoplasmic in the a-intercalated cells (arrows) in the cortical collecting duct. (D) S613F mutation patient
vHþ-ATPase expression is cytoplasmic in the a-intercalated cells (arrows) in the cortical collecting duct. (E) Sjogren’s patient vHþ-ATPase
expression is absent (arrows).
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Therefore, the cell model of autosomal dominant
dRTA is one of functionally normal (or near normal)
mutant kAE1 molecules forming hetero-oligomers
with wt kAE1 and causing retention in the endoplas-
mic reticulum (ER), with perhaps in some cases apical
mistargeting [4]. However, in native renal tissue the
evidence for cytosolic retention or aberrant targeting in
familial dRTA has been less clear. A recent report
using an antibody against both AE1 and AE2 could
not detect cell membrane-associated AE1 staining
in vHþ-ATPase positive cortical collecting duct cells
in native renal tissue from a patient with the R589H
mutation [7]. The increased AE1 immunoreactivity
that was seen did not correspond to cell boundaries
and the authors concluded that this was an artefact
capturing the peroxidase product in areas of nephro-
calcinosis. Thus, information on AE1 targeting
was uncertain because of the quality of the biopsy
material: the renal tissue had chronic scarring from
pyelonephritis, nephrocalcinosis and abscesses.
In contrast, the renal biopsy sample from our patient
with inherited dRTA had no major tissue abnormal-
ities and allowed a more detailed investigation of AE1
localization. In agreement with the in vitro data for the
S613F mutation [6], we found cytosolic staining for
AE1 in a-intercalated cells, but no clear basolateral or
apical staining. Our data confirm that the S613F AE1
protein is retained intracellularly in vivo and that it
seems to prevent wt AE1 from reaching the basolateral
membrane. Furthermore, we also observed a reduction
in apical vHþ-ATPase staining for the ubiquitous
E subunit present in a-intercalated cells, whereas the
weaker staining normally seen in the proximal tubule
was unaffected. In addition, the a-intercalated cells
seemed to be reduced in number and smaller in size.
Interestingly, a decline in a-intercalated cell number
has also been observed in rats chronically treated
with acetazolamide and in the carbonic anhydrase
2 knockout mouse [14].
A Korean study [15] reported vHþ-ATPase and
AE1 immunostaining in 11 patients with dRTA of
differing aetiology (idiopathic, tubulointerstitial and
autoimmune) and found that all dRTA renal biopsy
specimens had reduced or absent immunoreactivity
to vHþ-ATPase, and that approximately half had
negative AE1 immunoreactivity. Unfortunately, no
information was given about the aetiology in those
patients with absent AE1 staining, and no family
history or genetic information was available for those
patients with ‘idiopathic’ dRTA.
As well as occurring as a primary genetic disorder,
dRTA can also be secondary to other, often auto-
immune, conditions like Sjo¨gren’s syndrome.
Secondary dRTA in Sjo¨gren’s is common and human
tissue has been examined previously in three published
studies [11–13]. Cohen et al. [12] demonstrated a
lack of vHþ-ATPase immunostaining in the cortical
collecting ducts of renal biopsy tissue from a patient
with Sjo¨gren’s and Defranco et al. [13] also found
absent vHþ-ATPase and kAE1 immunostaining. These
authors examined the serum of their patients
and found no evidence of anti-Hþ-ATPase or anti-
intercalated cell antibodies, though Bastani and
colleagues [11] in another report detected auto-
antibodies against vHþ-ATPase. These findings and
ours suggest that different cellular events can underlie
dRTA. In our patient with inherited dRTA, altered
expression and location of AE1 and vHþ-ATPase was
observed, perhaps indicating some form of ‘coupling’
between the two proteins in their intracellular regula-
tion; whereas in the patient with autoimmune dRTA,
neither protein could be detected. The aberrant
localization and/or absence of these two major
a-intercalated cell acid–base transporters explains the
underlying acidification defect in both patients, and
highlights the differences in their pathogenesis.
However, there is still much to learn about the
interrelationship between these key transporter
proteins.
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